The effect of Emdogain and platelet-derived growth factor on the osteoinductive potential of hydroxyapatite tricalcium phosphate.
The aim of this study was to determine whether hydroxyapatite β-tricalcium phosphate (HA-TCP) either alone or coated with Emdogain (EMD) or recombinant human platelet-derived growth factor-BB (rhPDGF-BB) becomes osteoinductive in the murine thigh muscle model for osteoinduction. Twenty CD1 adult male mice had gelatin capsules implanted into the thigh muscle of both hind limbs. The capsules were either empty or contained one of the following: uncoated particulate HA-TCP, EMD-coated HA-TCP or rhPDGF-BB-coated HA-TCP. The implant sites were assessed histologically at 4 and 8 weeks. A semi-quantitative histological examination was performed to assess the inflammatory changes, reparative processes and osteoinduction within the graft site. At both 4 and 8 weeks, histological analysis failed to demonstrate any osteoinductive activity in any of the specimens from the experimental groups. A minimal chronic inflammatory response and foreign body reaction around the implanted materials was seen which reduced over time. The HA-TCP particles were embedded within fibrous connective tissue and were encapsulated by a dense cellular layer consisting of active fibroblasts and occasional macrophages with the thickness of this layer decreasing over time. The results of this study suggest that the use of commercially available HA-TCP alone or in combination with EMD or rhPDGF-BB is biocompatible but not osteoinductive in the murine thigh muscle model of osteoinduction. Coating HA-TCP with EMD or rhPDGF-BB does not enhance its osteoinductive potential.
Colgate Australian Clinical Dental Research Centre, School of Dentistry, University of Adelaide, Frome Road, Adelaide, South Australia 5005, Australia.
R C
RC
Chan
V
V
Marino
P M
PM
Bartold
D000818:Animals; D000077214:Becaplermin; D001672:Biocompatible Materials / Q000494:pharmacology*; D020099:Coated Materials, Biocompatible / Q000494:pharmacology*; D003238:Connective Tissue / Q000473:pathology; D003746:Dental Enamel Proteins / Q000494:pharmacology*; D005347:Fibroblasts / Q000473:pathology; D005355:Fibrosis; D005549:Foreign-Body Reaction / Q000473:pathology; D015726:Giant Cells / Q000473:pathology; D006801:Humans; D006882:Hydroxyapatites / Q000494:pharmacology*; D007249:Inflammation / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010012:Osteogenesis / Q000187:drug effects*; D020574:Proto-Oncogene Proteins c-sis / Q000494:pharmacology*; D052097:Quadriceps Muscle / Q000473:pathology; D011994:Recombinant Proteins; D013997:Time Factors
D001672:Biocompatible Materials; D020099:Coated Materials, Biocompatible; D003746:Dental Enamel Proteins; D006882:Hydroxyapatites; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; C109069:enamel matrix proteins; C074950:hydroxyapatite-beta tricalcium phosphate; D000077214:Becaplermin